Reipet – Lifestyle
Author:
ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
May 7, 2026
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
April 15, 2026
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
March 27, 2026
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
March 26, 2026